- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01497431
Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants
Phase I Multiple Dose Study of 12-Week Treatment by Se-Methyl-L-Cysteine(MSC) and L SeMet in Adult Males
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the individual toxicity profiles of Se-methyl-seleno-L-cysteine (methyl selenocysteine; MSC) and selenomethionine (SeMet) administered to cohorts of men daily for twelve weeks, with dose escalation with each successive cohort.
SECONDARY OBJECTIVES:
I. To measure the pharmacokinetics of selenium, according to form (MSC vs SeMet): MSC and SeMet impacts on plasma, albumin, and urinary concentrations of selenium over 48 hours on dosing days 1 and 84.
II. To evaluate the pharmacodynamics of selenium by form (MSC vs SeMet): plasma, albumin, and urinary Selenoprotein P (Sepp1) concentrations and glutathione peroxidase (GPx) activity over 48 hours on dosing days 1 and 84.
III. To store plasma and formed elements (red cells plus platelets) for future analysis of methyl selenol and other key selenium species, when those assays become available.
OUTLINE: This is a dose-escalation study. Participants are randomized to 1 of 3 treatment arms.
ARM I: Participants receive Se-methyl-seleno-L-cysteine orally (PO) on days 1-84.
ARM II: Participants receive selenomethionine PO on days 1-84.
ARM III: Participants receive placebo PO on days 1-84.
After completion of study treatment, patients are followed up on day 112.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
New York
-
Buffalo, New York, United States, 14263
- Roswell Park Cancer Institute
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt-Ingram Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Total body weight between 50 and 115 kg (110 and 250 lbs)
- Hemoglobin (Hgb) > 12 mg/dL
- Platelet count > 100,000/μL
- Absolute neutrophil count (ANC) > 1000/μL
- Creatinine =< institutional upper limit of normal (ULN)
- Serum glutamate pyruvate transaminase (SGPT) and serum glutamic oxaloacetic transaminase (SGOT) < 2.0 x ULN
- Total bilirubin =< ULN (participants with a higher level of bilirubin presumed due to familial metabolism will be considered on an individual basis)
- Life expectancy greater than 3 years
- Participants must agree to use adequate contraception (barrier method of birth control; abstinence) from time of screening until study completion (i.e., for at least 2 weeks after last dose of study drug)
- Ability to understand and the willingness to sign a written informed consent document
- Agree to refrain from use of selenium (Se) supplements (other than the 100 mcg dose common in multivitamins) or Se-containing drugs while on study between 30 days before study drug initiation and Day 84
Exclusion Criteria:
- Not willing to remain at Roswell Park Cancer Institute (RPCI), and in follow up, as required
- Presence of medical conditions which, in the opinion of the investigator, would place either the participant or the integrity of the data at risk
- Serum creatinine > ULN, SGOT or SGPT >= 2.0 x ULN, or bilirubin > ULN
- Treatment with an investigational drug within 30 days prior to the dose of study drug
- Use of selenium [Se] supplements greater than the 100 mcg dose common in multivitamins between 30 days before study drug initiation and Day 84
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to investigational agent (e.g., reaction to other Se supplements)
- Participants who have donated 1 unit of blood within 30 days prior to the first dose of investigational agent
- Eastern Cooperative Oncology Group (ECOG) performance status > 1
- Diagnosed with cancer, other than non-melanoma skin cancer, in last 2 years
- Under treatment for any cancer
- Use of glucose-lowering agents or a condition that would make a fast from 10:00 pm the evening before until 11:00 am on days 1 and 84 hazardous
- American Urological Association (AUA) total symptom score > 10 or any individual symptom score of greater than or equal to 4
- Psychiatric illness which would prevent compliance with the intervention or would prevent the patient from providing informed consent
- Medical conditions which in the opinion of the treating physician would make this protocol unreasonably hazardous for the participant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Arm I (Se-methyl-seleno L-cysteine)
Participants receive Se-methyl-seleno L-cysteine on days 1-84.
|
Correlative studies
Correlative studies
Other Names:
Given PO
Other Names:
|
EXPERIMENTAL: Arm II (selenomethionine)
Participants receive selenomethionine PO on days 1-84.
|
Correlative studies
Correlative studies
Other Names:
Given PO
Other Names:
|
PLACEBO_COMPARATOR: Arm III (placebo)
Participants receive placebo PO on days 1-84.
|
Correlative studies
Given PO
Other Names:
Correlative studies
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical toxicity of Se-methyl-seleno-L-cysteine according to the NCI CTCAE version 4.0
Time Frame: Up to 112 days
|
The safety and tolerability data will be summarized using descriptive statistics, by cohort and for all cohorts combined compared to placebo.
Reported adverse events will be looked at for possible differences, where appropriate, using graphical methods.
|
Up to 112 days
|
Clinical toxicity of Se-methyl-L-cysteine compared to selenium after multiple doses, according to the NCI CTCAE version 4.0
Time Frame: Up to 112 days
|
The safety and tolerability data will be summarized using descriptive statistics, by cohort and for all cohorts combined compared to placebo.
Reported adverse events will be looked at for possible differences, where appropriate, using graphical methods.
|
Up to 112 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Characterization of the pharmacokinetics of Se in the forms Se-methyl-seleno-L-cysteine and selenium at multiple doses
Time Frame: At baseline, and at and .5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hrs after dosing on days 1 and between days 70 and 84
|
The pharmacokinetic variables will be tabulated, and descriptive statistics calculated for each cohort, using established pharmacokinetic analysis methods.
Plasma and urine pharmacokinetic parameters will be summarized graphically and by arithmetic or geometric means and coefficients of variations for each cohort.
|
At baseline, and at and .5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hrs after dosing on days 1 and between days 70 and 84
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Protective Agents
- Trace Elements
- Micronutrients
- Antioxidants
- Anticarcinogenic Agents
- Selenium
- Selenomethylselenocysteine
Other Study ID Numbers
- NCI-2012-00085 (REGISTRY: CTRP (Clinical Trial Reporting Program))
- P30CA060553 (U.S. NIH Grant/Contract)
- N01CN35157 (U.S. NIH Grant/Contract)
- CDR0000717828
- I 182210 (OTHER: Northwestern University)
- NWU09-4-03 (OTHER: DCP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Carcinoma
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)UnknownCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the BoneUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Castration Levels of Testosterone | Stage IV Prostate AdenocarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedMetastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Hormone-Resistant Prostate Cancer | Stage IV Prostate AdenocarcinomaUnited States
-
University of WashingtonJanssen Research & Development, LLCTerminatedCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Double-Negative Prostate CarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer | PSA Progression | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the BoneUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnBiochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Oligometastatic Prostate CarcinomaUnited States
-
University of UtahCompletedMetastatic Prostate Carcinoma | Stage IV Prostate Cancer | Prostate Carcinoma Metastatic in the BoneUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingMetastatic Prostate Carcinoma | Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Hormone-Resistant Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterCompletedBiochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | PSA Progression | PSA Level Greater Than FiftyUnited States
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States